Evidence map›Paper›PMID 28661481›Full record

ArticleCell death & disease2017

Inefficient differentiation response to cell cycle stress leads to genomic instability and malignant progression of squamous carcinoma cells.

Pilar Alonso-Lecue, Isabel de Pedro, Vincent Coulon, Rut Molinuevo, Corina Lorz, Carmen Segrelles, Laura Ceballos, Daniel López-Aventín, Ana García-Valtuille, José M Bernal and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. The human Flower isoform hFWE4 facilitates cornification in cutaneous squamous cell carcinoma.JID innovations : skin science from molecules to population health · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Pilar Alonso-LecueCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Isabel de PedroCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Vincent CoulonInstitut de Genétique Moléculaire de Montpellier, CNRS/UM2, Montpellier, France.
Rut MolinuevoCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Corina LorzMolecular Oncology Unit, Department of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), CIBERONC, Madrid, Spain.
Carmen SegrellesMolecular Oncology Unit, Department of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), CIBERONC, Madrid, Spain.
Laura CeballosCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Daniel López-AventínDepartment of Dermatology, Hospital del Mar, Barcelona, Spain.
Ana García-ValtuilleClínica Mompía, Mompía, Spain.
José M BernalCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Francisco MazorraClínica Mompía, Mompía, Spain.
Ramón M PujolDepartment of Dermatology, Hospital del Mar, Barcelona, Spain.
Jesús ParamioMolecular Oncology Unit, Department of Basic Research, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), CIBERONC, Madrid, Spain.
J Ramón SanzCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Ana FreijeCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Agustí TollDepartment of Dermatology, Hospital del Mar, Barcelona, Spain.
Alberto GandarillasCell Cycle, Stem Cell Fate and Cancer Laboratory, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Instituto de Investigación Marqués de Valdecilla · ESHospital Del Mar · ESMarqués de Valdecilla University Hospital · ESCentro de Investigación Biomédica en Red de Cáncer · ESCentre National de la Recherche Scientifique · FRCentro de Investigaciones Energéticas, Medioambientales y Tecnológicas · ESCOMUE Languedoc-Roussillon Universités · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Squamous cell carcinoma (SCC) or epidermoid cancer is a frequent and aggressive malignancy. However in apparent paradox it retains the squamous differentiation phenotype except for very dysplastic lesions. We have shown that cell cycle stress in normal epidermal keratinocytes triggers a squamous differentiation response involving irreversible mitosis block and polyploidisation. Here we show that cutaneous SCC cells conserve a partial squamous DNA damage-induced differentiation response that allows them to overcome the cell division block. The capacity to divide in spite of drug-induced mitotic stress and DNA damage made well-differentiated SCC cells more genomically instable and more malignant in vivo. Consistently, in a series of human biopsies, non-metastatic SCCs displayed a higher degree of chromosomal alterations and higher expression of the S phase regulator Cyclin E and the DNA damage signal γH2AX than the less aggressive, non-squamous, basal cell carcinomas. However, metastatic SCCs lost the γH2AX signal and Cyclin E, or accumulated cytoplasmic Cyclin E. Conversely, inhibition of endogenous Cyclin E in well-differentiated SCC cells interfered with the squamous phenotype. The results suggest a dual role of cell cycle stress-induced differentiation in squamous cancer: the resulting mitotic blocks would impose, when irreversible, a proliferative barrier, when reversible, a source of genomic instability, thus contributing to malignancy.

Indexed as

CarcinogenesisCarcinoma, Squamous CellCell DifferentiationCyclin EDNA DamageDoxorubicinGene Expression Regulation, NeoplasticGenomic InstabilityHistonesHumansKeratinocytesMitosisPolyploidyPrimary Cell CultureSkin NeoplasmsCyclin EDoxorubicinH2AX protein, humanHistones

Identifiers

PMID28661481
PMCPMC5520915
OpenAlexW2728646881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.